AI Now Used to Design Vaccines, Human Trials Have Commenced
Artificial Intelligence (AI) is increasingly demonstrating its role within the healthcare sector. While previously used primarily for data analysis and drug discovery, AI is now being utilised to design vaccines that have entered the human clinical trial stage. This development is considered a major step that could transform how scientists develop vaccines in the future.
Researchers from the University of Cambridge have developed vaccine candidates where the antigen design was created using an AI system. This technology is capable of analysing millions of biological and genetic data points to identify the parts of a virus with the highest potential to trigger an immune response. The result is a vaccine design targeted to provide broader protection against various types of coronaviruses, including new variants that may emerge in the future.
Conventional vaccine development methods generally require years because scientists must conduct a series of laboratory experiments to determine the precise targets. With the assistance of AI, this process can be significantly accelerated. Artificial intelligence systems are capable of performing simulations and predictions in a much shorter timeframe compared to traditional methods, thereby speeding up the initial research stages.
Nevertheless, experts emphasise that AI does not replace the role of scientists or existing scientific processes. Once the vaccine design is generated by AI, the candidate must still undergo various stages of rigorous testing, ranging from laboratory research and animal testing to clinical trials in humans. The entire process is conducted to ensure the vaccine is safe and effective before it can be used widely.
The use of AI in vaccine development is also part of a growing trend in the global pharmaceutical industry. Various biotechnology companies and research institutions are now investing significant resources to leverage artificial intelligence to accelerate the discovery of new drugs and therapies. Some companies even aim to develop AI-based drug candidates where the entire initial design process is performed by computer systems.
Although initial results are promising, the success of AI-designed vaccines must still be proven through clinical trials spanning several phases. Researchers will monitor the safety, immune response, and effectiveness of the vaccine in trial participants before proceeding to the next stage.
If the entire process proceeds as expected, AI technology has the potential to accelerate the global response to the threat of infectious diseases and future pandemics. The ability to analyse large-scale data can assist scientists in designing new vaccines more rapidly, allowing public health protection efforts to be implemented in a shorter timeframe.